New study shows potential link between bodyweight and risk of severe COVID-19, especially for younger adults
29 April 2021
The first large study to report the effect of bodyweight on risk of worse outcomes from COVID-19 across the full range of body mass index (BMI) is published today in The Lancet Diabetes and Endocrinology journal.
12 April 2021
Inhaled budesonide, a common corticosteroid, is the world's first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants. As of today, the treatment is available in UK primary care on a case-by-case basis.
Favipiravir to be investigated as a possible COVID-19 treatment for at-home recovery in the PRINCIPLE trial
8 April 2021
Could the antiviral favipiravir help transform COVID-19 into an illness that can be successfully treated by general practitioners?
Risk of severe COVID-19 from asthma and other respiratory diseases may be only modestly increased, new analysis suggests
1 April 2021
People with asthma have only a modestly increased risk of developing severe Covid-19 and requiring admission to hospital from the illness, finds an analysis of 8.3 million electronic health care records in England led by University of Oxford researchers.
19 March 2021
Close monitoring and evaluation as schools reopen crucial to inform ongoing policy
3 March 2021
From today, the UK’s national priority platform trial of Covid-19 treatments for recovery at home launches its investigation of the gout drug colchicine, and expands for the first time to include adults of any age.
16 February 2021
More people in England at high risk from Covid-19 will get priority access to vaccines thanks to new technology developed by a University of Oxford-led team of researchers that can identify those who may be most vulnerable to the virus.
Azithromycin and doxycycline are not generally effective against COVID-19 in patients treated at home, shows PRINCIPLE trial
25 January 2021
Update from the Chief Investigators of the Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE), 25 January 2021
15 January 2021
A new study led by the University of Oxford has found that since the first coronavirus lockdown the number of people diagnosed with bowel cancer in England has fallen sharply, with a deficit persisting up to October 2020.
Inhaled corticosteroids to be investigated as a possible treatment for Covid-19 in national PRINCIPLE Trial
27 November 2020
In Covid-19, inhaled budesonide may prevent damaging inflammation, stop the virus from getting into lung cells and inhibit viral replication.
3 November 2020
Led by a research team in the Nuffield Department of Primary Care Health Sciences, the University of Oxford will take part in a new pilot scheme to assess the use of Lateral Flow Tests (LFTs), a new COVID-19 test designed to identify asymptomatic individuals with the virus.
Britain’s most influential Hindu temple spreads awareness of the PRINCIPLE trial among Indian community
21 October 2020
Europe’s BAPS Swaminarayan Sanstha, the largest Hindu temple outside of India, is supporting their community during the coronavirus pandemic by spreading awareness of the PRINCIPLE trial of Covid-19 treatments.
21 October 2020
A new risk model, developed by UK researchers to predict a person’s risk of being admitted to hospital and dying from Covid-19 has been published by The BMJ
1 October 2020
More than 1000 people across the UK have signed-up to take part in the UK-wide PRINCIPLE Trial of potential community-based treatments for COVID-19, led by Oxford University.
18 September 2020
Professor Mahendra G Patel, University of Bradford, joins PRINCIPLE Trial as National Black, Asian and minority ethnic Community and Pharmacy Lead
15 September 2020
Researchers have hailed a ‘fantastic’ response from more than 1,700 GP practices who have stepped forward to contribute patient data for vital COVID-19 research from the Nuffield Department of Primary Care Health Sciences – tripling the amount of data available.